Dental Care Clinics in Rogersville, TN Accepting Medicare
2 Dental Care Clinics found. Showing 1 - 2
 Rogersville Dental Center Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 110 S Hasson St, Rogersville, TN 37857 Phone: 606-359-5815 |
Rogersville Family Dentistry Dentist Medicare: Not Enrolled in Medicare Practice Location: 110 South Hasson Street, Rogersville, TN 37857 Phone: 423-272-5353 Fax: 423-272-0047 |
News Archive
Raccoon dogs potential intermediate host for SARS-CoV-2
Researchers at the Friedrich Loeffler Institute in Germany have conducted a study demonstrating that raccoon dogs were a potential intermediate host in the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
New research offers natural alternative to arthritis drugs
The research, conducted by The Australian Centre for Complementary Medicine Education and Research (ACCMER), shows that Biolane Green Lipped Mussel Extract has a combination of actions that are not associated with increased risk of blood clotting that has caused recent drug withdrawals and medical warnings. In fact, the product may even help slow the progression of osteoarthritis.
Targeting risk factors throughout life stages could prevent 35% of dementia cases, study reveals
A study published in The Lancet, on July 20th 2017, reveals that 1 out of 3 dementia cases are preventable when risk factors are targeted beginning from childhood.
Patients receiving individual doses and conventional breast radiation experience similar side effects
In a 10-year study of women who received radiation therapy to treat early-stage breast cancer, those receiving fewer, larger individual doses experienced similarly low rates of late-onset side effects as those undergoing conventional radiation therapy. Findings from the multi-institutional U.K. FAST clinical trial were presented last week at the 60th Annual Meeting of the American Society for Radiation Oncology.
IDM Pharma presents new data on IDM-2101 in non-small cell lung cancer
IDM Pharma, Inc. today announced follow-up results from the Phase 2 study of IDM-2101 showing that the product candidate was well tolerated, induced broadly specific cytotoxic T lymphocyte (CTL) responses, and showed a positive survival trend in HLA-A2 positive patients with non-small cell lung cancer (NSCLC) who were treated with IDM-2101, compared to a parallel external control group of HLA-A2 negative non-treated patients.
› Verified 2 days ago